Caribou Biosciences (CRBU) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to 1337.58%.
- Caribou Biosciences' EBIT Margin rose 5516500.0% to 1337.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 1708.08%, marking a year-over-year decrease of 2685800.0%. This contributed to the annual value of 1667.16% for FY2024, which is 13305300.0% down from last year.
- As of Q3 2025, Caribou Biosciences' EBIT Margin stood at 1337.58%, which was up 5516500.0% from 1783.95% recorded in Q2 2025.
- Caribou Biosciences' EBIT Margin's 5-year high stood at 61.84% during Q3 2023, with a 5-year trough of 1893.87% in Q1 2024.
- For the 5-year period, Caribou Biosciences' EBIT Margin averaged around 1105.49%, with its median value being 888.52% (2023).
- Per our database at Business Quant, Caribou Biosciences' EBIT Margin soared by 7484500bps in 2021 and then tumbled by -18273900bps in 2024.
- Over the past 5 years, Caribou Biosciences' EBIT Margin (Quarter) stood at 797.38% in 2021, then dropped by -4bps to 828.22% in 2022, then decreased by -27bps to 1052.33% in 2023, then crashed by -78bps to 1871.69% in 2024, then increased by 29bps to 1337.58% in 2025.
- Its last three reported values are 1337.58% in Q3 2025, 1783.95% for Q2 2025, and 1823.76% during Q1 2025.